Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: What happens after Sept. 30, 2011?

Currently, there are no commitments by us or TPL to provide additional working capital to PDS. PDS has cash resources available to continue as a going concern at least through September 30, 2011. p10

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

During fiscal 2010 and through the date of this filing we and TPL each contributed $580,000 to fund the working capital of PDS. We expect the contributions to continue in the future due to the working capital demands of PDS.

We continue to seek capital for our business, and this additional capital may be raised through the issuance of additional preferred stock.p12

Share
New Message
Please login to post a reply